About this trial
The goal of this trial is to learn whether adding the blood pressure medication baxdrostat (Baxfendy) to standard-of-care medical therapies will beneficially change the heart structure and function of adults who have high blood pressure, thickened left heart walls, and are at risk for heart or kidney disease.
To determine if baxdrostat improves heart structure and function, the participants will:
* take a baxdrostat or a placebo (a look-alike tablet that contains no drug) tablet once a day for 12 months * undergo a safe and non-invasive cardiac magnetic resonance imaging scan (to measure heart mass, stiffness and function) at the beginning of the study and 12 months later * visit the clinic for checkups and blood or urine tests 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months after taking the first tablet
Eligibility criteria
Qualifiers
Individuals ≥18 years of age who are willing and able to provide signed informed consent
History of hypertension (Systolic BP >140 and <170 mmHg)
Serum K+ ≥3.5 and <5.0 mmol/L at Screening
Interventricular septal (IVS) thickness by echocardiography: Female ≥1.2 cm or Male ≥1.3 cm
Disqualifiers
None
Trial design
Treatments tested in this trial
- Baxdrostat
- Placebo
Treatment groups
Sponsors and collaborators
Subodh Verma
Lead sponsor
Canadian Medical and Surgical Knowledge Translation Research Group
Sponsor institution
AstraZeneca
Collaborator